Do We Need Antifungal Stewardship?
Purpose of review
Invasive fungal infections (IFIs) are recognized as a significant health problem worldwide. Inappropriate use of antifungals contributes to antifungal resistance and emerging fungi. There is an urgent clinical need to limit inappropriate antifungal usage through judicious antifungal stewardship (AFS).
The main goals of AFS are optimized care, de-escalation or withdrawal of antifungal therapy when appropriate, reduced costs, and reduced fungal resistance, with no negative impact in terms of morbidity or mortality. AFS should be tailored for each institution and health-care system, and should be performed by an experienced and trained multidisciplinary team, based on education, bedside interventions, and daily collaboration with the microbiology department and pharmacy team. Performance measures are needed to evaluate the impact of AFS. It is recommended that AFS be implemented in a stepwise manner, with modest initial goals to enable demonstration of success in the short term.
Encouraging the appropriate use of antifungal drugs should help to decrease the incidence of IFIs, thereby reducing antifungal resistance.
KeywordsAntifungal Stewardship Invasive fungal infections Diagnosis Fungal resistance
Compliance with Ethical Standards
Conflict of Interest
The authors declare that they have no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
References and Recommended Reading
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 2.Whitney L, Bicanic T. Antifungal stewardhisp. In: Laundy M, Gilchrist M, Whitney L, editors. Antimicrobial stewardship. Oxford: University Press; 2016. p. 1–20.Google Scholar
- 3.Stanzani M, Sassi C, Battista G, Cavo M, Lewis RE. Improved radiographic imaging of invasive fungal disease: the cornerstone to antifungal stewardship in the hematology units? Curr Fungal Infect Rep. 2016. https://doi.org/10.1007/s12281-016-0258-1.
- 5.•• Urbancic KF, Thursky K, Kong DCM, Johnson PDR, Slavin MA. Antifungal stewardship: developments in the field. Curr Opin Infect Dis. 2018;31:490–8. https://doi.org/10.1097/QCO.0000000000000497 This very recent article very clearly describes the fundamental aspects of implementing a stewardship program.Google Scholar
- 10.Valerio M, Vena A, Rodríguez-González CG, de Vega EC, Mateos M, Sanjurjo M, et al. Repeated antifungal use audits are essential for selecting the targets for intervention in antifungal stewardship. Eur J Clin Microbiol Infect Dis. 2018;37:1993–2000. https://doi.org/10.1007/s10096-018-3335-2.CrossRefGoogle Scholar
- 13.Barlam TF, Cosgrove SE, Abbo LM, MacDougall C, Schuet AN, Septimus EJ, et al. Implementing an antibiotic stewardship program: guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America. Clin Infect Dis. 2016;62:e51–77. https://doi.org/10.1093/cid/ciw118.CrossRefGoogle Scholar
- 15.Nwankwo L, Periselneris J, Cheong J, Thompson K, Darby P, Leaver N, et al. A prospective real-world study of the impact of an antifungal stewardship program in a tertiary respiratory-medicine setting. Antimicrob Agents Chemother. 2018;62(10). https://doi.org/10.1128/AAC.00402-18.
- 19.•• Muñoz P, Valerio M, Vena A, Bouza E. Antifungal stewardship in daily practice and health economic implications. Mycoses. 2015;58(Suppl 2):14–25. https://doi.org/10.1111/myc.12329 This manuscript provides a step-by-step guides for the successful implementation of an AFS program.CrossRefGoogle Scholar
- 21.• Dellit TH, Owens RC, McGowan JE Jr, Gerding DN, Weinstein RA, Burke JP, et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis. 2007;44:159–77. https://doi.org/10.1086/510393. These are the guidelines issued by the IDSA which support programs for use of antimicrobials, including antifungals.CrossRefGoogle Scholar
- 23.Rouzé A, Loridant S, Poissy J, Dervaux B, Sendid B, Cornu M, et al. Biomarker-based strategy for early discontinuation of empirical antifungal treatment in critically ill patients: a randomized controlled trial. Intensive Care Med. 2017;43:1668–77. https://doi.org/10.1007/s00134-017-4932-8. CrossRefGoogle Scholar
- 26.Shah DN, Yau R, Weston J, Lasco TM, Salazar M, Palmer HR, et al. Evaluation of antifungal therapy in patients with candidaemia based on susceptibility testing results: implications for antimicrobial stewardship programmes. J Antimicrob Chemother. 2011;66:2146–51. https://doi.org/10.1093/jac/dkr244.CrossRefGoogle Scholar
- 28.Rzewuska M, Charani E, Clarkson JE, Davey PG, Duncan EM, Francis JJ, et al. Prioritizing research areas for antibiotic stewardship programmes in hospitals: a behavioural perspective consensus paper. Clin Microbiol Infect. 2019;25:163–8. https://doi.org/10.1016/j.cmi.2018.08.020.CrossRefGoogle Scholar
- 32.Bal AM, Shankland GS, Scott G, Imtiaz T, Macaulay R, McGill M. Antifungal step-down therapy based on hospital intravenous to oral switch policy and susceptibility testing in adult patients with candidaemia: a single centre experience. Int J Clin Pract. 2014;68:20–7. https://doi.org/10.1111/ijcp.12231.CrossRefGoogle Scholar